KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Emergent BioSolutions (EBS) Receivables - Net (2016 - 2025)

Emergent BioSolutions' Receivables - Net history spans 16 years, with the latest figure at $84.2 million for Q4 2025.

  • For Q4 2025, Receivables - Net fell 37.81% year-over-year to $84.2 million; the TTM value through Dec 2025 reached $84.2 million, down 37.81%, while the annual FY2025 figure was $84.2 million, 37.81% down from the prior year.
  • Receivables - Net reached $84.2 million in Q4 2025 per EBS's latest filing, down from $149.5 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $278.9 million in Q4 2021 to a low of $79.8 million in Q2 2025.
  • Average Receivables - Net over 5 years is $174.4 million, with a median of $167.1 million recorded in 2022.
  • The largest YoY upside for Receivables - Net was 49.78% in 2024 against a maximum downside of 49.39% in 2024.
  • A 5-year view of Receivables - Net shows it stood at $278.9 million in 2021, then crashed by 42.92% to $159.2 million in 2022, then increased by 19.97% to $191.0 million in 2023, then fell by 29.11% to $135.4 million in 2024, then crashed by 37.81% to $84.2 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Receivables - Net are $84.2 million (Q4 2025), $149.5 million (Q3 2025), and $79.8 million (Q2 2025).